Abstract
Investigation of the mechanisms of atherosclerosis has determined that inflammation plays a central role in the development, progression, and outcome of acute coronary syndrome (ACS). C-reactive protein (CRP) plasma levels increase in patients with ACS. CPR is an important prognostic marker in ACS, following angioplasty, and in the long-term management of post-infarction patients. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. This short review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these other APPs in ACS.
Keywords: Acute phase proteins, acute phase reactants, inflammation-sensitive plasma proteins, acute coronary syndrome, atherosclerosis, acute myocardial infarction
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Volume: 6 Issue: 4
Author(s): Michele Correale, Natale Daniele Brunetti, Luisa De Gennaro and Matteo Di Biase
Affiliation:
Keywords: Acute phase proteins, acute phase reactants, inflammation-sensitive plasma proteins, acute coronary syndrome, atherosclerosis, acute myocardial infarction
Abstract: Investigation of the mechanisms of atherosclerosis has determined that inflammation plays a central role in the development, progression, and outcome of acute coronary syndrome (ACS). C-reactive protein (CRP) plasma levels increase in patients with ACS. CPR is an important prognostic marker in ACS, following angioplasty, and in the long-term management of post-infarction patients. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. This short review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these other APPs in ACS.
Export Options
About this article
Cite this article as:
Correale Michele, Brunetti Daniele Natale, De Gennaro Luisa and Biase Di Matteo, Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome), Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (4) . https://dx.doi.org/10.2174/187152508785909537
DOI https://dx.doi.org/10.2174/187152508785909537 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renoprotective Potency of Heme Oxygenase-1 Induction in Rat Renal Ischemia-Reperfusion
Inflammation & Allergy - Drug Targets (Discontinued) Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
Recent Patents on Anti-Infective Drug Discovery Human Embryonic and Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery: Patents and Patented Uses
Recent Patents on Cardiovascular Drug Discovery Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Influence of Lifestyle Measures on Hypertriglyceridaemia
Current Drug Targets Teaching Pharmacogenetics in Low and Middle-Income Countries: Team Based Learning and Lessons Learned at the American University of Beirut
Current Pharmacogenomics and Personalized Medicine Virtual Screening for Cholesterol Absorption Inhibitors
Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Aβ Monomers, Oligomers and Fibrils: Structural Features
Current Bioactive Compounds ABC Transporters and Sterol Absorption
Current Drug Targets - Cardiovascular & Hematological Disorders Statin Therapy for Native and Peri-Interventional Coronary Heart Disease
Current Molecular Medicine